“Underpowered” Trials Unethical Unless In Early Phase Or Meta-Study – JAMA
This article was originally published in The Gray Sheet
Executive Summary
Early-phase, "underpowered" clinical trials of devices or drugs can be considered ethical only if designed to guide later pivotal studies, Scott Halpern, University of Pennsylvania School of Medicine, et al., write in the July 17 Journal of the American Medical Association
You may also be interested in...
Medtronic InSync ICD Gains Panel Support In Tiebreaking 6-5 Vote
The recommended post-market requirement for Medtronic's InSync ICD and its pacing counterpart suggests that companies that conduct pivotal studies with a small number of patients will be expected to follow up with a large trial
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.